CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2

(Molecular Therapy: Oncolytics 16, 100–110; March 2020) In the initially published version of this article, there was an error in Figure 5A. The western blot result of GAPDH in S1-MI-80 cells was erroneously duplicated in H460/MX20 cells. The experiments were repeated three times, independently. The ABCG2 protein bands of S1-MI-80 and H460/MX20 cells were measured and calculated against their own GAPDH protein bands. The new representative protein bands are shown below, and bar graphs are averages of three independent experiments. The authors apologize for this error and guarantee the correction would not change the description of the results and conclusion of the paper. The corrected versions of Figure 5A and 5B are provided below. CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2Xu et al.Molecular Therapy - OncolyticsDecember 26, 2019In BriefThe overexpression of ATP-binding cassette (ABC) transporters is one of the important mechanisms of multidrug resistance (MDR). Some tyrosine kinase inhibitors (TKIs) such as CM082 might be a potential ABC transporter inhibitor, thus potentially reversing MDR. We used a 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay to determine the cytotoxicity and reversal effect of CM082. A xenograft model was established to evaluate the reversal MDR efficacy in vivo. The intracellular accumulation and efflux of ABCG2 substrates were measured by flow cytometry. Full-Text PDF Open Access